[go: up one dir, main page]

PE20110992A1 - Composicion inmunogenica que comprende un antigeno del virus del dengue - Google Patents

Composicion inmunogenica que comprende un antigeno del virus del dengue

Info

Publication number
PE20110992A1
PE20110992A1 PE2011001431A PE2011001431A PE20110992A1 PE 20110992 A1 PE20110992 A1 PE 20110992A1 PE 2011001431 A PE2011001431 A PE 2011001431A PE 2011001431 A PE2011001431 A PE 2011001431A PE 20110992 A1 PE20110992 A1 PE 20110992A1
Authority
PE
Peru
Prior art keywords
dengue
immunogenic composition
composition including
adjuvant
antigen
Prior art date
Application number
PE2011001431A
Other languages
English (en)
Inventor
Benoit Baras
Dirk Gheysen
Isabelle Solange Lucie Knott
Jean-Paul Prieels
Jean-Francois Toussaint
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42174405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110992(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20110992A1 publication Critical patent/PE20110992A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE UN ANTIGENO DEL VIRUS DEL DENGUE INACTIVADO SELECCIONADO DE UN ANTIGENO DEL VIRUS DEL DENGUE-1, DENGUE-2, DENGUE-3 O DENGUE-4 Y UN ADYUVANTE SIN ALUMINIO, DONDE EL ADYUVANTE COMPRENDE UNA EMULSION DE ACEITE EN AGUA QUE COMPRENDE UN ACEITE METABOLIZABLE TAL COMO EL ESCUALENO, UN TOCOL Y UN EMULSIONANTE TAL COMO MONOOLEATO DE POLIOXIETILENO SORBITANO
PE2011001431A 2009-02-17 2010-02-16 Composicion inmunogenica que comprende un antigeno del virus del dengue PE20110992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15306009P 2009-02-17 2009-02-17

Publications (1)

Publication Number Publication Date
PE20110992A1 true PE20110992A1 (es) 2012-02-12

Family

ID=42174405

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001630A PE20151588A1 (es) 2009-02-17 2010-02-16 Vacuna contra el virus del dengue
PE2011001431A PE20110992A1 (es) 2009-02-17 2010-02-16 Composicion inmunogenica que comprende un antigeno del virus del dengue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015001630A PE20151588A1 (es) 2009-02-17 2010-02-16 Vacuna contra el virus del dengue

Country Status (23)

Country Link
US (2) US9265821B2 (es)
EP (1) EP2398821B1 (es)
JP (2) JP6058266B2 (es)
KR (1) KR101738704B1 (es)
CN (1) CN102395600B (es)
AR (1) AR075437A1 (es)
AU (1) AU2010215595A1 (es)
BR (1) BRPI1011224A2 (es)
CA (1) CA2752809A1 (es)
CL (1) CL2011001993A1 (es)
CO (1) CO6551750A2 (es)
DO (1) DOP2011000268A (es)
ES (1) ES2649020T3 (es)
IL (1) IL214385A (es)
MX (1) MX338898B (es)
NZ (1) NZ700477A (es)
PE (2) PE20151588A1 (es)
PH (1) PH12015501637A1 (es)
SG (2) SG173194A1 (es)
TW (2) TW201517915A (es)
UY (1) UY32457A (es)
WO (1) WO2010094663A1 (es)
ZA (1) ZA201105656B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1011224A2 (pt) * 2009-02-17 2016-03-15 Glaxosmithkline Biolog Sa vacina contra vírus da dengue inativado com adjuvante livre de alumínio
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
EP2719395A1 (en) 2010-09-01 2014-04-16 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
KR20140033171A (ko) * 2011-05-26 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 비활성화된 뎅기 바이러스 백신
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
WO2017197035A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
JP7195147B2 (ja) * 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
EP3558351B1 (en) * 2016-12-23 2022-01-26 Intervet International B.V. Combination vaccine for swine
EP3678695A1 (en) * 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
EP3845639A4 (en) * 2018-08-27 2022-05-11 Mican Technologies Inc. PROCEDURE FOR EVALUATION OF ANTIINFECTIVES, VACCINES ETC. USING IMMORTALIZED MONOCYTIC CELLS AND INDUCED CELLS
CN111150849A (zh) * 2020-04-02 2020-05-15 广州隽沐生物科技股份有限公司 一种组合物及其制备方法及其应用
CN114377122B (zh) * 2022-01-18 2023-04-07 四川大学 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途
WO2023147337A2 (en) * 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
EP0729473B1 (en) 1993-11-17 2000-08-23 OM Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
DE69838992T2 (de) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
SI1126876T1 (sl) * 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
WO2000057907A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
AU776638B2 (en) 1999-03-26 2004-09-16 Walter Reed Army Institute Of Research Adaptation of virus to vertebrate cells
HK1044484B (en) * 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
CA3114957C (en) 2001-05-22 2022-02-08 Stephen S. Whitehead Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
EP1942932B1 (en) 2005-08-08 2013-05-08 Oregon Health and Science University Inactivating pathogens with hydrogen peroxide for vaccine production
JP4828189B2 (ja) * 2005-09-14 2011-11-30 雅美 森山 分泌型ＩｇＡ及びＩｇＧ抗体誘導剤
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
BRPI1011224A2 (pt) * 2009-02-17 2016-03-15 Glaxosmithkline Biolog Sa vacina contra vírus da dengue inativado com adjuvante livre de alumínio

Also Published As

Publication number Publication date
IL214385A (en) 2016-11-30
TWI528972B (zh) 2016-04-11
US20160120972A1 (en) 2016-05-05
IL214385A0 (en) 2011-09-27
CL2011001993A1 (es) 2012-04-09
SG173194A1 (en) 2011-09-29
JP6104988B2 (ja) 2017-03-29
TW201517915A (zh) 2015-05-16
JP6058266B2 (ja) 2017-01-11
TW201043245A (en) 2010-12-16
EP2398821A1 (en) 2011-12-28
EP2398821B1 (en) 2017-08-30
PE20151588A1 (es) 2015-11-18
UY32457A (es) 2011-01-31
AU2010215595A1 (en) 2011-08-25
SG2014014385A (en) 2014-04-28
MX2011008649A (es) 2011-09-06
MX338898B (es) 2016-05-03
JP2012517979A (ja) 2012-08-09
CO6551750A2 (es) 2012-10-31
ES2649020T3 (es) 2018-01-09
DOP2011000268A (es) 2012-07-31
US20110318407A1 (en) 2011-12-29
CN102395600A (zh) 2012-03-28
KR101738704B1 (ko) 2017-06-08
NZ700477A (en) 2016-04-29
PH12015501637A1 (en) 2019-12-11
WO2010094663A1 (en) 2010-08-26
KR20110132379A (ko) 2011-12-07
CA2752809A1 (en) 2010-08-26
US9265821B2 (en) 2016-02-23
JP2015221803A (ja) 2015-12-10
AR075437A1 (es) 2011-03-30
ZA201105656B (en) 2012-04-25
BRPI1011224A2 (pt) 2016-03-15
CN102395600B (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
PE20110992A1 (es) Composicion inmunogenica que comprende un antigeno del virus del dengue
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
CL2012000976A1 (es) Composicion antitranspirante que comprende una base, un activo antiperspirante y por lo menos un antioxidante; y metodo para reducir o eliminar la coloracion amarilla en las prendas de vestir.
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
PE20140646A1 (es) Vacuna de virus de dengue inactivado
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
UY35131A (es) Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
PE20160027A1 (es) Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
MX349720B (es) Composiciones adyuvantes novedosas.
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
UY34851A (es) Inhibidores macrocíclicos de virus flaviviridae
BR112012013469A2 (pt) composições orais contendo extratos de garcinia mangostana l. e métodos relacionados
CL2011002282A1 (es) Procedimiento para tratar agua natural o residual que contiene mg o al y uno o mas contaminantes cationicos y anionicos, que comprende agregar a dicha agua por lo menos un compuesto que contiene mg o al para formar un hidroxido de doble capa (ldh) con mg y al como especies predominantes en el reticulo de ldh.
UY33897A (es) Inhibidores del virus de la hepatitis c
MX343172B (es) Composiciones y metodos para administracion de vacunas contra virus del dengue.
CO6650413A2 (es) Conjugador para prevención o el tratamiento de la adicción a la nicotina
HN2012001262A (es) Nuevos derivados de 8heterociclo-piperidina condensada)-( piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona y su utilizacion como inhibidores de p75
RU2011134486A (ru) Агент, повышающий экспрессию редокс-факторов
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
PE20151248A1 (es) Derivados de ciclopentano como inhibidores de catepsinas
MX2015005112A (es) Composicion inmunogenica contra la aeromonas hydrophila.
MX336980B (es) Combinacion y composicion para el tratamiento de obesidad.

Legal Events

Date Code Title Description
FC Refusal